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Abstract
Background: There are inconsistencies in the literature on reproductive and genital health determinants of human
papillomavirus (HPV) infection, the primary cause of cervical cancer. We examined these factors in the Ludwig-
McGill Cohort Study, a longitudinal, repeated-measurements investigation on the natural history of HPV infection.
Methods: We analyzed a cohort subset of 1867 women with one complete year of follow-up. We calculated odds
ratios (OR) and 95 % confidence intervals (CI) for reproductive and genital health characteristics from questionnaire
and laboratory data in relation to 1-year period prevalence of HPV infection. Two outcomes were measured; the
first based on phylogenetic grouping of HPV types based on tissue tropism and oncogenicity (Alphapapillomavirus
Subgenus 1: species 1, 8, 10 and 13; Subgenus 2: species 5, 6, 7, 9, 11; Subgenus 3: species 3, 4 and 14) and the
second based on transient or persistent HPV infections.
Results: Lifetime (Subgenus 3 OR = 2.00, CI: 1.23–3.24) and current (Subgenus 3 OR = 2.00, CI: 1.15–3.47) condom
use and use of contraceptive injections (Subgenus 1 OR = 1.96, CI: 1.22–3.16, Subgenus 2 OR = 1.34, CI: 1.00–1.79)
were associated with increased risk of HPV infection. Intrauterine device use was protective (Subgenus 1 OR = 0.48,
CI: 0.30–0.75, Subgenus 2 OR = 0.78, CI: 0.62–0.98). These factors were not associated with persistence of HPV
infection. Tampon use, previous gynecologic infections and cervical inflammation were associated with an overall
increased risk of HPV infection.
Conclusions: Cervical HPV infection was associated with reproductive and genital health factors. Further studies are
necessary to confirm the low to moderate associations observed.
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Background
Cervical cancer is the fourth most common cancer in
women worldwide [1]. Despite recent advances in hu-
man papillomavirus (HPV) vaccines and screening pro-
grams, cervical cancer remains a large global health
burden. HPV is a necessary cause of cervical cancer, but
it is not sufficient. Therefore, identification of risk
factors of HPV infection and cervical cancer may inform
preventive strategies. Outside of sexual behavior charac-
teristics and parity [2–4], there is a lack of consensus in
the literature on determinants of HPV infection, particu-
larly with respect to reproductive and genital health.
Condom use has been inconsistently associated with a
decreased risk of HPV infection [5, 6]. Use of oral con-
traceptives (OCs) is associated with cervical carcinogen-
esis [7, 8], while use of intrauterine devices (IUDs) [9]
and tubal sterilization [10] seems protective. However,
evidence of a relationship between these factors and risk
of HPV infection remains equivocal as there have been
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very few studies done in this field [10, 11]. An elevated
risk of HPV infection is associated with other infections
such as Chlamydia trachomatis [12, 13], human im-
munodeficiency virus (HIV) [14, 15], and bacterial vagin-
osis (BV) [16]. Despite these trends, inconsistencies
remain concerning the magnitude and direction of ef-
fects, with a paucity of information on other factors.
This study focuses on the role of reproductive and
genital health on cervical HPV infections using data
from a large longitudinal study conducted to investigate
the natural history of HPV infection.
Methods
Study design and participants
The design and methods of the Ludwig-McGill Cohort
Study have been previously described [17]. The study en-
rolled women from São Paulo, Brazil, a high-risk area
for cervical cancer. Briefly, women were recruited from
a maternal and child health program for low-income
families between 1993 and 1997. Eligible women must
have: 1) been 18–60 years old 2) been permanent resi-
dents of São Paulo 3) had no intention of becoming
pregnant over the next year 4) had an intact uterus with-
out referral for hysterectomy 5) had no treatment for
cervical disease within 6 months previous to enrolment
and 6) reported no use of vaginal medication in the
2 days prior to enrolment. Signed, informed consent for
participation in the study was obtained from all women.
Follow-up of women occurred every 4 months in the
first year and twice per year afterwards. The study was
approved by the institutional review boards and ethical
committees of McGill University, University of Toronto,
the Ludwig Institute for Cancer Research and the
Maternidade Escola Vila Nova Cachoeirinha clinic.
Data collection and procedures
Questionnaires were administered by one of two study
nurses (MLB, LG) at each of the four visits in the first
year and once per year afterwards. Baseline question-
naires collected detailed information on sexual and re-
productive histories, and behavioural characteristics
including smoking and hygiene habits. Cervical speci-
mens were taken at each visit for conventional Pap cy-
tology and molecular HPV testing. Ectocervical and
endocervical cells were collected using an Accelon bio-
sampler (Medscand Inc., Hollywood, FL). Pap smears
were read and graded at the Jewish General Hospital
(Montreal, Canada).
Presence of HPV DNA was detected using polymerase
chain reaction to amplify a highly conserved segment
of the L1 viral gene using PGMY consensus primers
[18, 19]. Typing of the amplified product was per-
formed by hybridization with individual oligonucleotide
probes, and by restriction fragment-length polymorphism
analysis to identify 40 different mucosal HPV types. We
grouped types according to Alphapapillomavirus species
clusters that exhibit comparable tissue tropism and bio-
logical behavior concerning cancer risk [20–23]. Subgenus
1 included HPV types 6, 11, 32, 40, 42, 44 and 54, from
species α1, α8, α10 and α13. Subgenus 2 included HPV
types 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, 67, 68, 69, 70, 73 and 82, from species α5, α6, α7,
α9 and α11. Subgenus 3 included HPV types 57, 61, 62,
71, 72, 81, 83, 84 and 89, from species α3, α4 and α14.
Subgenus 1 and Subgenus 3 HPV types are part of sub-
genera whose members are not carcinogenic, whereas
types in Subgenus 2 are mostly carcinogenic. Types in all
three subgenus groups exhibit strong genital tropism but
types from Subgenus 3 are mostly commensal agents that
infect the vagina but produce no clinically identifiable
lesions [20–23].
Exposure measurements and study outcomes
Aside from questions with predetermined answer choices,
responses to open-ended questions were grouped into cat-
egorical variables, including comments disclosed to the
administering nurses, but not explicitly asked (Additional
file 1: Table S1). Some exposures were classified as
“former”, indicating lifetime use and “current”, indicating
use between the first and second visit as use between visits
remained relatively constant over the first year of
follow-up. We also grouped qualitative cytology re-
sults, which included reports on inflammation and
bacterial or fungal infections into categories relating
to cervical health conditions.
We used two HPV outcome variables. First, we con-
sidered 1-year period prevalence for infections from the
above three phylogenetically-defined subgenus groups by
taking into account HPV types detected cumulatively
over the first four visits in the first year (enrolment and
months 4, 8 and 12). Second, we categorized HPV in-
fections into mutually exclusive transient or persistent
infections in the first year. Transient HPV infections
were those involving one positive HPV test result
followed by two subsequent negative results. Persist-
ent infections were two or more positive HPV test re-
sults of the same HPV group, with no more than one
negative result between two positive test results. HPV
test results that did not fall into these definitions
were excluded.
Statistical analysis
We estimated odds ratios (ORs) and 95 % confidence in-
tervals (CIs) for HPV outcomes using logistic regression
models, adjusting for a priori (baseline age and lifetime
number of sexual partners) and empirical confounders.
The latter, identified using a 5 % change-in-estimate
strategy, included race, marital status, education, age at
Shaw et al. BMC Infectious Diseases  (2016) 16:116 Page 2 of 10
first intercourse, age at menarche, number of pregnancies,
smoking, alcohol drinking and years since last Pap smear.
For the analysis of 1-year period prevalence, we com-
pared women with a specific group infection (Subgenus
1 = 108, Subgenus 2 = 495, Subgenus 3 = 131) to a float-
ing control group of those who did not have that group
infection. We called this the non-restricted analysis.
Since concurrent and cumulative multiple-type infec-
tions were common in the cohort, we conducted separ-
ate analyses restricted to women who only harboured
infections with HPV types from a single phylogenetic
group (Subgenus 1 = 41, Subgenus 2 = 377, Subgenus 3
= 57). A fixed control group that included only HPV-
negative women (n = 1267) was used in these restricted
analyses. The restricted analyses, while compromising
on precision, were intended to increase the validity of
observed associations and were thus used to confirm as-
sociations seen in the non-restricted estimates. Adjusted
ORs were calculated using the non-restricted crude
estimate. All data were analyzed using Stata 12.0 (Stata-
Corp, College Station, TX, USA).
Results
Of the 3589 eligible women, 2528 participants were en-
rolled in the Ludwig-McGill cohort study (Fig. 1), with
an average follow-up time of 7 years. This analysis was
restricted to 1867 women who had completed all four
visits within the first year, representing 76 % of those en-
rolled in the study. Of these, 1267 women were HPV-
negative and 600 women tested positive for any HPV in-
fection on at least one of the four visits. Due to multiple
infections in some women, there were a total of 734
type-specific HPV infections. For the second outcome
indicator, there were 262 transient HPV infections, 282
persistent infections and 56 women were excluded from
this analysis. At baseline, the mean age of participants
was 32.9 (±8.7) years, and the mean number of lifetime
sexual partners and pregnancies were 3.9 and 3.5,
Fig. 1 Flow chart of the selection of analytical study sample population. The study sample included a subset of 1867 women with one complete year
of follow-up from the Ludwig-McGill Cohort Study population. Two outcomes were considered. The first was based on phylogenetic grouping
of HPV types based on tissue tropism and oncogenicity (Alphapapillomavirus Subgenus 1, 2 and 3). The second outcome was based on
transient or persistent HPV infections
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respectively. Only 19 % of women had completed high
school or further education. Characteristics of this study
population according to outcome variables are described
in Additional file 1: Table S2.
Table 1 presents associations for reproductive and
genital health factors with the first outcome of phylogen-
etic grouping of HPV types (Additional file 1: Table S3
refers to the restricted subsets). Results from the re-
stricted crude analyses tended to reflect those of the
non-restricted crude and adjusted analyses apart from
the expected loss in precision in the restricted estimates.
Table 2 presents these associations for the second out-
come of transient and persistent infections.
Contraceptive methods
Both former (OR = 2.00, 95 % CI: 1.23–3.24) and current
(OR = 2.00, 95 % CI: 1.15–3.47) condom use was signifi-
cantly associated with an increased prevalence of
Subgenus 3 HPV infections. Current condom use was
also significantly associated with transient HPV infec-
tions (OR = 1.47, 95 % CI: 1.00–2.16). OC use was not
significantly associated with any HPV outcome analyzed.
Use of IUDs was protective across all HPV outcomes
with significant effects in Subgenus 1 (OR = 0.48, 95 %
CI: 0.30–0.75), Subgenus 2 (OR = 0.78, 95 % CI: 0.62–
0.98) and transient (OR = 0.65, 95 % CI: 0.48–0.87) in-
fections. Tubal sterilization had a predominantly pro-
tective, although insignificant, effect across all outcomes.
Of the open-ended responses, use of contraceptive injec-
tions increased the prevalence of all HPV outcomes,
with Subgenus 1 (OR = 1.96, 95 % CI: 1.22–3.16),
Subgenus 2 (OR = 1.34, 95 % CI: 1.00–1.79) and transi-
ent (OR = 1.58, 95 % CI: 1.10–2.26) HPV infections
being statistically significant. Natural and external prod-
ucts were not significantly associated with any HPV out-
come, although there were not enough observations to
calculate Subgenus 1 ORs.
Vaginal hygiene
Menstrual cloth use had a protective effect for Subgenus
2, transient and persistent HPV infections with a signifi-
cant effect on Subgenus 1 infections (OR = 0.54, 95 %
CI: 0.32–0.91). Conversely, all point estimates for hy-
gienic tampon use were above the null with Subgenus 2
infections approaching borderline significance and tran-
sient infections being statistically significant (OR = 1.48,
95 % CI: 1.00–2.20). Frequent douching was not associ-
ated with most HPV outcomes, although there was a sig-
nificantly protective effect on Subgenus 3 infections
(OR = 0.11, 95 % CI: 0.02–0.81). There was also no effect
of the types of douching products used, with the ex-
ception of “unknown” products and Subgenus 3 HPV
infections (OR = 2.92, 95 % CI: 1.20–7.12). Lastly,
genital discomfort, recent discomfort and reported
pain/bleeding were not associated with any HPV in-
fection outcome.
Gynecologic products
In general, no significant associations or trends were ob-
served with the use of gynecologic products and some
categories lacked observations. Of note, both former
(OR = 2.09, 95 % CI: 1.10–3.98) and current (OR = 2.50,
95 % CI: 1.23–5.08) antibiotic use were associated with
persistent HPV infections, while current antibiotic use
(OR = 5.95, 95 % CI: 1.14–30.97) and former antifungal
use (OR = 5.14, 95 % CI: 1.17–22.52) were significantly
associated with Subgenus 1 infections. No significant
trends were observed with the use of homemade gyne-
cologic products, other than use of “unknown” home-
made products and Subgenus 3 infections (OR = 5.33,
95 % CI: 1.80–15.85) and persistent HPV infections
(OR = 3.20, 95 % CI: 1.00–10.24). Due to low num-
bers of women using these products, the CIs were
very wide, indicating low precision in the estimates.
Vaginal health
From information volunteered by the participant and
not explicitly asked in questionnaires, there were no sig-
nificant associations between cervical ectropion and any
HPV infection outcome. A self-report of gynecologic
surgery was associated with an increased prevalence of
Subgenus 1 HPV infections (OR = 2.05, 95 % CI: 1.11–
3.79). Information on previous gynecologic infections or
treatments volunteered by the participant was also
associated with a significant increase in prevalence of
Subgenus 1 HPV infections (OR = 1.73, 95 % CI: 1.13–
2.65) with no association with other HPV outcomes.
When previous history of gynecologic infections was
explicitly asked, there were no significant associations
between non-HPV-related infections and any HPV in-
fection outcome. There was, however, a significant in-
crease between previous HPV-related infections and
Subgenus 1 (OR = 3.87, 95 % CI: 2.09–7.14), Subgenus 2
(OR = 2.02, 95 % CI: 1.27–3.19), transient (OR = 3.23,
95 % CI: 1.91–5.47) and persistent (OR = 2.46, 95 %
CI: 1.40–4.31) HPV infections. Using qualitative notes
from the cytology reports, there were no significant
associations with bacterial or fungal infections and
any HPV infection. General inflammation was positively
associated with Subgenus 1 (OR = 2.10, 95 % CI: 1.37–
3.22), Subgenus 2 (OR = 1.53, 95 % CI: 1.21–1.94),
transient (OR = 1.73, 95 % CI: 1.27–2.35) and persistent
(OR = 1.62, 95 % CI: 1.20–2.19) HPV infections.
Discussion
This study provides novel insights on reproductive
health and vaginal hygiene factors in HPV infection.
While some of these factors seemed to be associated
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Table 1 Associations between reproductive health and vaginal hygiene factors and the 1-year period prevalence of HPV infection
by phylogenetic group in the Ludwig-McGill cohort study
Variable Subgenus 1a (n = 108) Subgenus 2a (n = 495) Subgenus 3a (n = 131)
ORb 95 % CI ORb 95 % CI ORb 95 % CI
Reproductive Health Factors
Condom Use
Former vs. Never 1.28 0.79, 2.07 0.90 0.71, 1.15 2.00 1.23, 3.24
Current vs. Never 1.43 0.83, 2.48 1.09 0.82, 1.45 2.00 1.15, 3.47
Oral Contraceptives
< 6 years vs. Never 1.25 0.66, 1.38 0.98 0.71, 1.35 1.40 0.83, 2.37
6+ years vs. Never 1.23 0.60, 2.53 1.00 0.70, 1.43 0.62 0.32, 1.19
Intrauterine Device
Yes vs. No 0.48 0.30, 0.75 0.78 0.62, 0.98 0.73 0.49, 1.08
Tubal Sterilization
Yes vs. No 1.24 0.65, 1.36 0.84 0.59, 1.21 0.65 0.33, 1.30
Contraceptive Injection
Yes vs. No 1.96 1.22, 3.16 1.34 1.00, 1.79 1.34 0.83, 2.17
Natural Products
Yes vs. No - - 0.37 0.13, 1.05 0.74 0.17, 3.20
Vaginal Products
Yes vs. No - - 0.82 0.37, 1.81 0.32 0.04, 2.40
Genital Health and Hygiene Factors
Menstrual Cloth
Yes vs. No 0.54 0.32, 0.91 0.93 0.74, 1.18 1.02 0.68, 1.53
Hygienic Tampon
Yes vs. No 1.49 0.87, 2.54 1.33 0.98, 1.81 1.30 0.79, 2.14
Douching
Frequent vs. Infrequent 1.20 0.53, 2.69 1.29 0.83, 2.00 0.11 0.02, 0.81
Douching Products
Natural vs. None 0.96 0.60, 1.54 0.92 0.72, 1.17 0.90 0.57, 1.41
Medical vs. None 1.09 0.23, 5.15 0.97 0.46, 2.06 2.75 0.98, 7.73
Unknown vs. None 1.18 0.27, 5.22 0.51 0.21, 1.21 2.92 1.20, 7.12
Genital Discomfort
Yes vs. No 0.96 0.64, 1.45 0.96 0.78, 1.20 0.89 0.60, 1.31
Recent Discomfort
Yes vs. No 0.99 0.65, 1.50 1.11 0.89, 1.38 1.22 0.84, 1.75
Pain or Bleeding
Yes vs. No 2.83 0.59, 13.51 1.14 0.34, 3.75 0.91 0.12, 7.00
Gynecologic Products
Antibiotic
Former vs. Never 3.86 0.86, 17.34 0.83 0.51, 1.33 1.43 0.52, 3.97
Current vs. Never 5.95 1.14, 30.97 0.97 0.53, 1.79 1.84 0.56, 6.02
Antifungal
Former vs. Never 5.14 1.17, 22.52 1.10 0.70, 1.75 1.85 0.68, 5.02
Current vs. Never 1.64 0.22, 12.24 1.06 0.56, 2.02 1.74 0.49, 6.11
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with adverse or protective effects regarding cervical
HPV infection, they largely did not play an appreciable
role on the risk of infection in the Ludwig-McGill cohort
study population.
Previous studies [5] have demonstrated various direc-
tions of effect in condom use and HPV infection, despite
the underlying hypothesis of condoms being protective.
In our study, condom use seemed to be a risk marker
for Subgenus 3 HPV infections, which have tropism for
vaginal tissue. We did not measure frequency of condom
use, thus it is possible that women who reported con-
dom use, but did not consistently use them during
sexual intercourse, could still be exposed to HPV. Sexual
behaviour could play a role in these associations. Upon
stratifying by marital status and number of lifetime
sexual partners, the risk-marker effect of condom use
was stronger in women who were not in stable rela-
tionships (single, separated or widowed) and in
women with three or more lifetime sexual partners at
baseline (data not shown).
IUD use was associated with an overall protective ef-
fect, consistent with other studies [24, 25]. While our
study did not measure differences in use between copper
and hormonal IUDs, which release progestin to prevent
Table 1 Associations between reproductive health and vaginal hygiene factors and the 1-year period prevalence of HPV infection
by phylogenetic group in the Ludwig-McGill cohort study (Continued)
Abrasion
Former vs. Never - - 1.68 0.40, 7.72 - -
Current vs. Never - - 1.10 0.08, 16.23 - -
External Products
Former vs. Never 0.75 0.20, 2.84 - - - -
Current vs. Never 1.36 0.48, 3.89 - - - -
Unknown Products
Former vs. Never 2.82 0.64, 12.42 0.96 0.62, 1.49 2.21 0.81, 6.01
Current vs. Never 3.44 0.63, 18.68 1.10 0.60, 2.03 2.82 0.83, 9.53
Home-made Products
Natural vs. None 1.22 0.78, 1.92 0.91 0.72, 1.15 0.98 0.66, 1.47
Medical vs. None 0.80 0.27, 2.40 1.26 0.77, 2.04 0.76 0.29, 2.02
Unknown vs. None 2.75 0.53, 14.15 1.33 0.45, 3.91 5.33 1.80, 15.82
Vaginal Health Characteristics
Cervical Ectropion
Yes vs. No 0.37 0.05, 2.77 0.89 0.42, 1.91 0.74 0.17, 3.10
Gynecologic Surgery
Yes vs. No 2.05 1.11, 3.79 0.90 0.60, 1.37 0.89 0.42, 1.89
Gynecologic Treatment/Infection
Yes vs. No 1.73 1.13, 2.65 1.17 0.92, 1.50 1.26 0.83, 1.89
Previous Gynecologic Infection
HPV vs. None 3.87 2.09, 7.14 2.02 1.27, 3.19 1.21 0.54, 2.71
Non-HPV vs. None 1.33 0.81, 2.19 1.03 0.78, 1.34 1.27 0.82, 1.97
Cytology Observations
Bacterial Infection
Yes vs. No 1.28 0.63, 2.63 1.30 0.88, 1.91 1.31 0.68, 2.52
Fungal Infection
Yes vs. No 1.25 0.61, 2.54 1.29 0.88, 1.87 1.48 0.83, 2.66
General Inflammation
Yes vs. No 2.10 1.37, 3.22 1.53 1.21, 1.94 1.12 0.74, 1.69
a Subgenus 1 (HPVs-6, 11, 32, 40, 42, 44, 54 and 55), Subgenus 2 (HPVs-16, 18, 26 31, 33–35, 39, 45, 51–53, 56, 58, 59, 66–70, 73 and 82) and Subgenus 3 (HPVs-57,
61, 62, 71, 72, 81, 83, 84 and 89) infections were determined based on the phylogenetic classification of HPV types
b Odds ratios were adjusted for age, lifetime number of sexual partners and empirical confounders (identified using a 5 % change in estimate strategy) such as
race, marital status, education, age at first intercourse, age at menarche, number of pregnancies, smoking, alcohol drinking and years since last Pap smear
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fertilization, the protective effect on Subgenus 2 HPV in-
fections could have resulted from a low-level immune
response triggered by IUDs in the uterine endometrium
and cervix. There was a general protective trend with
tubal sterilization, which could be associated with behav-
ioural factors, as tubal sterilization was more common
in women in stable relationships. Moreover, due to the
irreversibility of the procedure, it is more common in
Table 2 Associations between reproductive health and vaginal






ORc 95 % CI ORc 95 % CI
Reproductive Health Factors
Condom Use
Former vs. Never 1.33 0.95, 1.86 1.06 0.77, 1.46
Current vs. Never 1.47 1.00, 2.16 1.24 0.86, 1.80
Oral Contraceptives
< 6 years vs. Never 1.16 0.76, 1.75 1.02 0.69, 1.52
6+ years vs. Never 0.90 0.56, 1.46 1.14 0.73, 1.77
Intrauterine Device
Yes vs. No 0.65 0.48, 0.87 0.77 0.57, 1.03
Tubal Sterilization
Yes vs. No 0.78 0.47, 1.28 0.75 0.46, 1.23
Contraceptive Injection
Yes vs. No 1.58 1.10, 2.26 1.31 0.91, 1.89
Natural Products
Yes vs. No 0.17 0.02, 1.31 0.46 0.14, 1.55
Vaginal Products
Yes vs. No 0.88 0.30, 2.56 0.76 0.26, 2.21
Genital Health and Hygiene Factors
Menstrual Cloth
Yes vs. No 1.00 0.74, 1.36 0.79 0.58, 1.06
Hygienic Tampon
Yes vs. No 1.48 1.00, 2.20 1.42 0.96, 2.08
Douching
Frequent vs. Infrequent 1.10 0.60, 2.00 1.12 0.62, 2.01
Douching Products
Natural vs. None 0.86 0.62, 1.19 0.80 0.57, 1.12
Medical vs. None 0.82 0.28, 2.40 1.70 0.72, 4.02
Unknown vs. None 0.36 0.09, 1.51 1.03 0.37, 2.87
Genital Discomfort
Yes vs. No 0.87 0.65, 1.18 0.89 0.67, 1.20
Recent Discomfort
Yes vs. No 1.06 0.79, 1.41 1.22 0.93, 1.59
Pain or Bleeding
Yes vs. No 0.61 0.07, 5.03 0.90 0.18, 4.48
Gynecologic Products
Antibiotic
Former vs. Never 1.00 0.53, 1.89 2.09 1.10, 3.98
Current vs. Never 0.89 0.37, 2.15 2.50 1.23, 5.08
Antifungal
Former vs. Never 1.74 0.94, 3.20 1.51 0.81, 2.82
Current vs. Never 1.52 0.67, 3.45 1.80 0.78, 4.13
Table 2 Associations between reproductive health and vaginal
hygiene and transient or persistent HPV infections in the
Ludwig-McGill cohort study (Continued)
Abrasion
Former vs. Never 4.17 0.49, 35.27 2.47 0.40, 15.26
Current vs. Never 5.40 0.26, 113.29 - -
External Products
Former vs. Never 1.46 0.18, 11.99 0.91 0.08, 10.66
Current vs. Never 6.43 0.65, 63.70 - -
Unknown Products
Former vs. Never 1.03 0.58, 1.84 1.14 0.65, 2.02
Current vs. Never 1.31 0.62, 2.81 1.93 0.95, 3.93
Home-made Products
Natural vs. None 1.00 0.74, 1.37 0.93 0.69, 1.26
Medical vs. None 0.97 0.47, 1.98 0.77 0.38, 1.56
Unknown vs. None 1.17 0.24, 5.73 3.20 1.00, 10.24
Vaginal Health Characteristics
Cervical Ectropion
Yes vs. No 1.01 0.41, 2.52 0.81 0.30, 2.19
Gynecologic Surgery
Yes vs. No 1.22 0.72, 2.04 1.39 0.86, 2.25
Gynecologic Infection/Treatment
Yes vs. No 0.90 0.65, 1.24 1.14 0.84, 1.54
Previous Gynecologic Infection
HPV vs. None 3.23 1.91, 5.47 2.46 1.40, 4.31
Non-HPV vs. None 0.95 0.66, 1.37 1.15 0.82, 1.61
Cytology Observations
Bacterial Infection
Yes vs. No 1.16 0.69, 1.95 1.45 0.91, 2.31
Fungal Infection
Yes vs. No 1.05 0.63, 1.75 1.24 0.77, 2.01
General Inflammation
Yes vs. No 1.73 1.27, 2.35 1.62 1.20, 2.19
a Transient HPV infections were defined as one positive test result in the first
four visits, followed by two subsequent negative results
b Persistent HPV infections were defined as two or more positive HPV test
results over the first four visits, with no more than one negative result
between two positive test results
c Odds ratios were adjusted for age, lifetime number of sexual partners and
empirical confounders (identified using a 5 % change in estimate strategy)
such as race, marital status, education, age at first intercourse, age at menarche,
number of pregnancies, smoking, alcohol drinking and years since last Pap smear
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older women. Thus, there could be an effect of age in
this interaction as protective effect was predominantly
seen in women over 30 years of age (data not shown). It
is also possible that the protective effects for IUD use
and tubal ligation may have resulted from low viral
transmission in low-risk partnerships. Although we con-
trolled for empirical confounders, these were based on
female interviews. We did not have behavior data on
male partners, which would have allowed us to verify the
low-risk partnership hypothesis.
Contraceptive injection use was associated with an in-
creased prevalence of Subgenus 1, Subgenus 2 and
transient HPV infections. While previous studies have
shown an increased association with cervical cancer
[7, 26], few studies have investigated the role of
contraceptive injections in HPV infection. There is
precedence for a hormonal effect of progestogen-only
contraceptives in increasing susceptibility or persistence
of HPV infection (compared to combined OCs containing
estrogen and progestin) [27, 28]. Sexual behaviour could
also be a factor as contraceptive injection/Norplant use
was more prevalent in women with three or more lifetime
sexual partners (16.9 % vs. 12.9 %).
Use of menstrual cloths had a slightly protective effect
on HPV infections, while use of hygienic tampons had
an adverse effect. Use of menstrual cloths has not previ-
ously been studied in association with HPV infection
and there does not appear to be a biological mechanism
for this protective effect. Very limited evidence exists for
an association between tampon use and risk of HPV infec-
tion. Some studies show no association [29], while some
report a positive association between tampon use and
high-risk HPV infection [30]. We speculate that tampon
use can lead to dryness and irritation in the vagina and
cervix [31], thereby increasing susceptibility to HPV infec-
tions through possible tearing or microabrasions.
Gynecologic product use served as a proxy for vaginal
health conditions. Our results suggest that bacterial in-
fections and use of products to control these infections
may play a role in increasing susceptibility to HPV infec-
tion. BV has been positively associated with HPV infec-
tions [16], which is biologically plausible. A lack of
protective lactobacilli in the vaginal flora during BV can
increase susceptibility to infections, such as Chlamydia
trachomatis, Neisseria gonorrhoeae, HSV-1 and 2, HIV
[32] and possibly HPV infections.
Previous gynecologic infections were associated with
increased prevalence of Subgenus 1 infections, which we
hypothesize to be related to BV. Self-reports of HPV-
related infections were significantly associated with all
outcomes, except for Subgenus 3 infections. Women
who reported a previous HPV-related infection could
have an increased risk of re-infection due to sexual be-
haviours or, just as plausibly, redetection of a latent HPV
infection. General inflammation noted in cytology re-
sults was significantly associated with all HPV outcomes
other than Subgenus 3 infections. A possible link be-
tween inflammation and cervical carcinogenesis might
exist. There are indications that chronic inflammation or
inflammation from other infections may play a role in
increasing risk of HPV infection [13], possibly explaining
this association.
Surprisingly, cervical ectropion was not associated
with any HPV outcome. The location of the transform-
ation zone can affect potential exposure to HPV infec-
tion and risk of cervical cancer [22]. Our results must be
taken with reservation as this was not explicitly asked in
the questionnaire. Due to mild symptoms, if any at all,
women may not be aware of the condition unless diag-
nosed by gynecological examination, leading to potential
misclassification. We found a positive association be-
tween gynecologic surgery and Subgenus 1 HPV infec-
tions. Most surgeries were dilation and curettage, a
procedure sometimes used to further diagnose a sus-
pected HPV infection in the endocervix. This might ex-
plain the observed positive association, as some cases of
gynecologic surgery may be in women who were already
HPV-infected.
In restricting our analysis to only women with one full
year of follow-up, we may have introduced a selection
bias. However, we believe that this enhanced internal
validity and efficiency in defining the HPV outcome vari-
ables. Furthermore, losses to follow-up in the first year
did not play a significant role as preliminary analyses of
the non-restricted data yielded similar results. We classi-
fied type-specific HPV outcomes into groups based on
phylogenetic relatedness to guide the statistical search
for predictors on the basis of viral behavior and tropism.
We were unable to study individual type-specific infec-
tions due to lack of precision.
Several limitations need to be underscored. Due to the
low-income setting of the study clinics where patients
were recruited from, the study population was very spe-
cific, with respect to cultural and social norms. Secondly,
outside of qualitative observations from cytology reports,
exposure measurements were based on self-reported re-
sponses. As this study pertains to sexual histories and
behaviour, there is a possible social desirability bias
where women, especially those with riskier sexual behav-
iours, would tend to answer questions on sensitive topics
in a socially acceptable manner. Additionally, poor recall,
especially on lifetime exposures, might be at play. While
we anticipate that any possible exposure misclassifica-
tion would be non-differential to outcome status,
women with a previous history of gynecologic infections
may be more conscious of the products they have previ-
ously used. In addition, the Ludwig-McGill cohort study
was not designed to investigate measures of vaginal
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health and hygiene as a primary objective. This post hoc
analysis considered exposure measures that predomin-
antly served as proxies for vaginal conditions. Because
several of these conditions are often asymptomatic or
characterized by mild symptoms, women may not have
been aware of these conditions. Lastly, there could still
be residual confounding due to unmeasured variables,
particularly related to male behaviors.
Conclusions
This study presents detailed analyses on the effects of
vaginal health and hygiene factors, some of which
seemed to be associated with risk of HPV infection dif-
ferentially by subgenus grouping based on propensity to
colonize different lower genital tract tissue subsites. Fur-
ther research using hypothesis-driven designs with more
accurate measures of exposure is necessary to examine
the observed associations.
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